These files comprise the publicly available data for the COG-UK hospital-onset COVID-19 infection study. The individual CSV files provided are: - HOCI_public_dataset: Anonymized version of main study dataset, with one row per HOCI case included in the final analysis - HOCI_public_varlist: Variable descriptions for main study dataset - epi_data_combined: Weekly data on total SARS-CoV-2 +ve (cov_pos_epi) and -ve (cov_neg_epi) inpatients at each study site -community_incidence_summary: Weekly local community incidence data for each study site, per 100,000 people per week, obtained from UK government testing dashboard and weighted according to outer postcodes of inpatients at each site.

Notes on anonymisation: HOCI_public_dataset is an anonymised version of the main HOCI study database. In order to fully anonymise individuals, and because the focus of the study was on infection control actions rather than patient outcomes, all individual-level patient demographic and clinical characteristics have been removed. Site and ward names have been changed to anonymized codes, and all free text fields have been removed as some of these contained unblinded details of hospitals and wards. All date fields have been removed, with study week of SARS-CoV-2 +ve test result for each HOCI case provided.

Notes on acronyms: In ‘HOCI_public_varlist’, the following acronyms are used: AGP, aerosol-generating procedure CR, contact restrictions CT, contact tracing DIPC, Director of IPC HCAI, healthcare-associated infection HCW, healthcare worker IPC, infection prevention and control SR, sequence report SRO, sequence report output QM, quality management

Socio-demographic characteristics and weighted prevalence of anti-SARS CoV-2 of 1,495 participants in two hospitals in Athens.

Updates

• Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.

  • CDC Weekly case and death counts (national and state level)
  • CDC County level cases and deaths
  • HHS New hospital admissions
  • CDC NowCast COVID variant proportions (national and regional level)

• April 9, 2020

  • The population estimate data for New York County, NY has been updated to include all five New York City counties (Kings County, Queens County, Bronx County, Richmond County and New York County). This has been done to match the Johns Hopkins COVID-19 data, which aggregates counts for the five New York City counties to New York County.

• April 20, 2020

  • Johns Hopkins death totals in the US now include confirmed and probable deaths in accordance with CDC guidelines as of April 14. One significant result of this change was an increase of more than 3,700 deaths in the New York City count. This change will likely result in increases for death counts elsewhere as well. The AP does not alter the Johns Hopkins source data, so probable deaths are included in this dataset as well.

• April 29, 2020

  • The AP is now providing timeseries data for counts of COVID-19 cases and deaths. The raw counts are provided here unaltered, along with a population column with Census ACS-5 estimates and calculated daily case and death rates per 100,000 people. Please read the updated caveats section for more information.

• September 1st, 2020

  • Johns Hopkins is now providing counts for the five New York City counties individually.

• February 12, 2021

  • The Ohio Department of Health recently announced that as many as 4,000 COVID-19 deaths may have been underreported through the state’s reporting system, and that the "daily reported death counts will be high for a two to three-day period."
  • Because deaths data will be anomalous for consecutive days, we have chosen to freeze Ohio's rolling average for daily deaths at the last valid measure until Johns Hopkins is able to back-distribute the data. The raw daily death counts, as reported by Johns Hopkins and including the backlogged death data, will still be present in the new_deaths column.

• February 16, 2021

  - Johns Hopkins has reconciled Ohio's historical deaths data with the state.

  Overview

The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.

The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.

This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.

The AP is updating this dataset hourly at 45 minutes past the hour.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Queries

Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic

• Filter cases by state here

• Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac

• Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true

• Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.

• Pull the 100 counties with the highest per-capita confirmed cases here

• Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.

Interactive

The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.

@(https://datawrapper.dwcdn.net/nRyaf/15/)

Interactive Embed Code

<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>

Caveats

• This data represents the number of cases and deaths reported by each state and has been collected by Johns Hopkins from a number of sources cited on their website.
• In some cases, deaths or cases of people who've crossed state lines -- either to receive treatment or because they became sick and couldn't return home while traveling -- are reported in a state they aren't currently in, because of state reporting rules.
• In some states, there are a number of cases not assigned to a specific county -- for those cases, the county name is "unassigned to a single county"
• This data should be credited to Johns Hopkins University's COVID-19 tracking project. The AP is simply making it available here for ease of use for reporters and members.
• Caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
• Population estimates at the county level are drawn from 2014-18 5-year estimates from the American Community Survey.
• The Urban/Rural classification scheme is from the Center for Disease Control and Preventions's National Center for Health Statistics. It puts each county into one of six categories -- from Large Central Metro to Non-Core -- according to population and other characteristics. More details about the classifications can be found here.

Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here

Attribution

This data should be credited to Johns Hopkins University COVID-19 tracking project

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

COVID-19 pandemic has changed in-hospital care and was linked to superimposed infections. Here, we described epidemiology and risk factors for hospital-acquired bloodstream infections (HA-BSIs), before and during COVID-19 pandemic. This retrospective, observational, single-center real-life study included 14,884 patients admitted to hospital wards and intensive care units (ICUs) with at least one blood culture, drawn 48 h after admission, either before (pre-COVID, N = 7382) or during pandemic (N = 7502, 1203 COVID-19+ and 6299 COVID-19–). Two thousand two hundred and forty-five HA-BSI were microbiologically confirmed in 14,884 patients (15.1%), significantly higher among COVID-19+ (22.9%; ptrend < .001). COVID-19+ disclosed a significantly higher mortality rate (33.8%; p < .001) and more ICU admissions (29.7%; p < .001). Independent HAI-BSI predictors were: COVID-19 (OR: 1.43, 95%CI: 1.21–1.69; p < .001), hospitalization length (OR: 1.04, 95%CI: 1.03–1.04; p < .001), ICU admission (OR: 1.38, 95%CI: 1.19–1.60; p < .001), neoplasms (OR:1.48, 95%CI: 1.34–1.65; p < .001) and kidney failure (OR: 1.81, 95%CI: 1.61–2.04; p < .001). Of note, HA-BSI IRs for Acinetobacter spp. (0.16 × 100 patient-days) and Staphylococcus aureus (0.24 × 100 patient-days) peaked during the interval between first and second pandemic waves in our National context. Patients with HA-BSI admitted before and during pandemic substantially differed. COVID-19 represented a risk factor for HA-BSI, though not confirmed in the sole pandemic period. Some etiologies emerged between pandemic waves, suggesting potential COVID-19 long-term effect on HA-BSIs.

BackgroundCOVID-19 is generally believed to increase the risk of nosocomial infections, however, there is a gap in relevant researches on critically ill patients in cardiac care units (CCU).MethodThis cross-sectional research was conducted in a tertiary-level non-epidemic hospital of Beijing, capital of China. The nosocomial infection rates of CCU were assessed prior to and during the of COVID-19 outbreak.ResultsDuring the COVID-19 pandemic, the overall incidence of nosocomial infections decreased by 20.6-percent compared with the pre - pandemic period. Specifically, the total nosocomial infection rate during the COVID-19 pandemic (p = 0.04) decreased by 20.6%. Among various types of CCU-acquired nosocomial infections, the rates of pneumonia, urinary tract infection (UTI), bloodstream infection (BSI), gastrointestinal infection, and skin infection decreased by ranges from 4.7 to 100% during the COVID-19 pandemic. Meanwhile, a 1.5-percent increase in ventilator-associated events (VAEs) was observed during the COVID-19 pandemic.ConclusionDuring the COVID-19 pandemic, stricter implementation of infection control protocols appears to reduce nosocomial infections in CCU.

After May 3, 2024, this dataset and webpage will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, and hospital capacity and occupancy data, to HHS through CDC’s National Healthcare Safety Network. Data voluntarily reported to NHSN after May 1, 2024, will be available starting May 10, 2024, at COVID Data Tracker Hospitalizations.

The following dataset provides facility-level data for hospital utilization aggregated on a weekly basis (Sunday to Saturday). These are derived from reports with facility-level granularity across two main sources: (1) HHS TeleTracking, and (2) reporting provided directly to HHS Protect by state/territorial health departments on behalf of their healthcare facilities.

The hospital population includes all hospitals registered with Centers for Medicare & Medicaid Services (CMS) as of June 1, 2020. It includes non-CMS hospitals that have reported since July 15, 2020. It does not include psychiatric, rehabilitation, Indian Health Service (IHS) facilities, U.S. Department of Veterans Affairs (VA) facilities, Defense Health Agency (DHA) facilities, and religious non-medical facilities.

For a given entry, the term “collection_week” signifies the start of the period that is aggregated. For example, a “collection_week” of 2020-11-15 means the average/sum/coverage of the elements captured from that given facility starting and including Sunday, November 15, 2020, and ending and including reports for Saturday, November 21, 2020.

Reported elements include an append of either “_coverage”, “_sum”, or “_avg”.

• A “_coverage” append denotes how many times the facility reported that element during that collection week.
• A “_sum” append denotes the sum of the reports provided for that facility for that element during that collection week.
• A “_avg” append is the average of the reports provided for that facility for that element during that collection week.

The file will be updated weekly. No statistical analysis is applied to impute non-response. For averages, calculations are based on the number of values collected for a given hospital in that collection week. Suppression is applied to the file for sums and averages less than four (4). In these cases, the field will be replaced with “-999,999”.

A story page was created to display both corrected and raw datasets and can be accessed at this link: https://healthdata.gov/stories/s/nhgk-5gpv

This data is preliminary and subject to change as more data become available. Data is available starting on July 31, 2020.

Sometimes, reports for a given facility will be provided to both HHS TeleTracking and HHS Protect. When this occurs, to ensure that there are not duplicate reports, deduplication is applied according to prioritization rules within HHS Protect.

For influenza fields listed in the file, the current HHS guidance marks these fields as optional. As a result, coverage of these elements are varied.

For recent updates to the dataset, scroll to the bottom of the dataset description.

On May 3, 2021, the following fields have been added to this data set.

• hhs_ids
• previous_day_admission_adult_covid_confirmed_7_day_coverage
• previous_day_admission_pediatric_covid_confirmed_7_day_coverage
• previous_day_admission_adult_covid_suspected_7_day_coverage
• previous_day_admission_pediatric_covid_suspected_7_day_coverage
• previous_week_personnel_covid_vaccinated_doses_administered_7_day_sum
• total_personnel_covid_vaccinated_doses_none_7_day_sum
• total_personnel_covid_vaccinated_doses_one_7_day_sum
• total_personnel_covid_vaccinated_doses_all_7_day_sum
• previous_week_patients_covid_vaccinated_doses_one_7_day_sum
• previous_week_patients_covid_vaccinated_doses_all_7_day_sum

On May 8, 2021, this data set is the originally reported numbers by the facility. This data set may contain data anomalies due to data key entries.

On May 13, 2021 Changed vaccination fields from sum to max or min fields. This reflects the maximum or minimum number reported for that metric in a given week.

On June 7, 2021 Changed vaccination fields from max or min fields to Wednesday reported only. This reflects that the number reported for that metric is only reported on Wednesdays in a given week.

On January 19, 2022, the following fields have been added to this dataset:

• inpatient_beds_used_covid_7_day_avg
• inpatient_beds_used_covid_7_day_sum
• inpatient_beds_used_covid_7_day_coverage

On April 28, 2022, the following pediatric fields have been added to this dataset:

• all_pediatric_inpatient_bed_occupied_7_day_avg
• all_pediatric_inpatient_bed_occupied_7_day_coverage
• all_pediatric_inpatient_bed_occupied_7_day_sum
• all_pediatric_inpatient_beds_7_day_avg
• all_pediatric_inpatient_beds_7_day_coverage
• all_pediatric_inpatient_beds_7_day_sum
• previous_day_admission_pediatric_covid_confirmed_0_4_7_day_sum
• previous_day_admission_pediatric_covid_confirmed_12_17_7_day_sum
• previous_day_admission_pediatric_covid_confirmed_5_11_7_day_sum
• previous_day_admission_pediatric_covid_confirmed_unknown_7_day_sum
• staffed_icu_pediatric_patients_confirmed_covid_7_day_avg
• staffed_icu_pediatric_patients_confirmed_covid_7_day_coverage
• staffed_icu_pediatric_patients_confirmed_covid_7_day_sum
• staffed_pediatric_icu_bed_occupancy_7_day_avg
• staffed_pediatric_icu_bed_occupancy_7_day_coverage
• staffed_pediatric_icu_bed_occupancy_7_day_sum
• total_staffed_pediatric_icu_beds_7_day_avg
• total_staffed_pediatric_icu_beds_7_day_coverage
• total_staffed_pediatric_icu_beds_7_day_sum

Due to changes in reporting requirements, after June 19, 2023, a collection week is defined as starting on a Sunday and ending on the next Saturday.

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

Weekly COVID-19 Community Levels (CCLs) have been replaced with levels of COVID-19 hospital admission rates (low, medium, or high) which demonstrate >99% concordance by county during February 2022–March 2023. For more information on the latest COVID-19 status levels in your area and hospital admission rates, visit United States COVID-19 Hospitalizations, Deaths, and Emergency Visits by Geographic Area.

This archived public use dataset contains historical case and percent positivity data updated weekly for all available counties and jurisdictions. Each week, the dataset was refreshed to capture any historical updates. Please note, percent positivity data may be incomplete for the most recent time period.

This archived public use dataset contains weekly community transmission levels data for all available counties and jurisdictions since October 20, 2022. The dataset was appended to contain the most recent week's data as originally posted on COVID Data Tracker. Historical corrections are not made to these data if new case or testing information become available. A separate archived file is made available here (: Weekly COVID-19 County Level of Community Transmission Historical Changes) if historically updated data are desired.

Related data CDC provides the public with two active versions of COVID-19 county-level community transmission level data: this dataset with the levels as originally posted (Weekly Originally Posted dataset), updated weekly with the most recent week’s data since October 20, 2022, and a historical dataset with the county-level transmission data from January 22, 2020 (Weekly Historical Changes dataset).

Methods for calculating county level of community transmission indicator The County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making.

CDC core metrics of and thresholds for community transmission levels of SARS-CoV-2 Total New Case Rate Metric: "New cases per 100,000 persons in the past 7 days" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. "New cases per 100,000 persons in the past 7 days" is considered to have a transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00).

Test Percent Positivity Metric: "Percentage of positive NAAT in the past 7 days" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests conducted

Dataset description

Daily official UK Covid data. The data is available per country (England, Scotland, Wales and Northern Ireland) and for different regions in England. The different regions are split into two different files as part of the data is directly gathered by the NHS (National Health Service). The files that contain the word 'nhsregion' in their name, include data related to hospitals only, such as number of admissions or number of people in respirators. The files containing the word 'region' in their name, include the rest of the data, such as number of cases, number of vaccinated people or number of tests performed per day. The next paragraphs describe the columns for the different file types.

Region files

Files related to regions (word 'region' included in the file name) have the following columns: - "date": date in YYYY-MM-DD format - "area type": type of area covered in the file (region or nation) - "area name": name of area covered in the file (region or nation name) - "daily cases": new cases on a given date - "cum cases": cumulative cases - "new deaths 28days": new deaths within 28 days of a positive test - "cum deaths 28days": cumulative deaths within 28 days of a positive test - "new deaths_60days": new deaths within 60 days of a positive test - "cum deaths 60days": cumulative deaths within 60 days of a positive test - "new_first_episode": new first episodes by date - "cum_first_episode": cumulative first episodes by date - "new_reinfections": new reinfections by specimen data - "cum_reinfections": cumualtive reinfections by specimen data - "new_virus_test": new virus tests by date - "cum_virus_test": cumulative virus tests by date - "new_pcr_test": new PCR tests by date - "cum_pcr_test": cumulative PCR tests by date - "new_lfd_test": new LFD tests by date - "cum_lfd_test": cumulative LFD tests by date - "test_roll_pos_pct": percentage of unique case positivity by date rolling sum - "test_roll_people": unique people tested by date rolling sum - "new first dose": new people vaccinated with a first dose - "cum first dose": cumulative people vaccinated with a first dose - "new second dose": new people vaccinated with a first dose - "cum second dose": cumulative people vaccinated with a first dose - "new third dose": new people vaccinated with a booster or third dose - "cum third dose": cumulative people vaccinated with a booster or third dose

Country files

Files related to countries (England, Northern Ireland, Scotland and Wales) have the above columns and also: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

NHS Region files

Files related to nhsregion (word 'nhsregion' included in the file name) have the following columns: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

It's worth noting that the dataset hasn't been cleaned and it needs cleaning. Also, different files have different null columns. This isn't an error in the dataset but the way different countries and regions report the data.

Demographic and clinical characteristics of Ranong hospital staff.

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size is USD 29845.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 2.90% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 11938.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.1% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 8953.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 6864.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1492.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 596.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.6% from 2024 to 2031.
Hospital held the highest Hospital-Acquired Infection Diagnostic market revenue share in 2024.

Market Dynamics of Hospital-Acquired Infection Diagnostic Market

Key Drivers for Hospital-Acquired Infection Diagnostic Market

Growing Prevalence of HAIs to Increase the Demand Globally

The Hospital-Acquired Infections Diagnostics Market is primarily driven by the ongoing increase in HAIs worldwide. The growing prevalence of these diseases highlights how important it is to have efficient diagnostic tools to recognize and treat infections contracted when a patient is in a medical facility. In the United States, an HAI affects around 1 in every 31 hospitalized patients at any given moment, according to Centers for Disease Control and Prevention (CDC) research. This means that 633,300 individuals get an HAI each year. Every year, the healthcare system in the United States sees more than a million HAIs. Tens of thousands of people lose their lives as a result of these illnesses every year, which can cause serious morbidity and death. According to estimates, HAIs cost billions of dollars a year.

Source: https://psnet.ahrq.gov/primer/health-care-associated-infections.

Rising Collaboration to Propel Market Growth

The increasing collaboration among the key players is expected to propel the market growth over the projected period. For instance, in February 2023, Roche announced that it has strengthened its research and innovation efforts by expanding its partnership with Janssen Biotech Inc. (Janssen) to develop companion diagnostics for targeted treatments. With several companion diagnostics technologies, such as immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays, Roche and Janssen now have more opportunities to work together in the precision medicine space thanks to the new, enlarged partnership.

Source: https://diagnostics.roche.com/global/en/news-listing/2023/roche-expands-collaboration-with-janssen-to-advance-personalised.html.

Restraint Factor for the Hospital-Acquired Infection Diagnostic Market

High Cost and Lack of Skilled Personnel to Limit the Sales

The cost of advanced diagnostic equipment and technologies may prevent them from being widely used, particularly in poor countries with tighter budgets and in smaller healthcare facilities. The entire cost of healthcare may also rise due to the high cost of reagents and equipment. Furthermore, the proficiency of medical practitioners influences the efficacy of diagnostic procedures. Market expansion may be hampered by a lack of qualified laboratory workers and medical professionals versed in the use of cutting-edge diagnostic equipment.

Impact of Covid-19 on the Hospital-Acquired Infection Diagnostic Market

The hospital-acquired infection (HAI) diagnostic market has been impacted by the COVID-19 pandemic in several ways. While there have been several difficulties, there have also been fresh prospects and developments in healthcare procedures that may ultimately be advantageous to the market. Due to the pandemic, financial investments, manpower, and equipment were reallocated to the COVID-19 management effort. This change took resources and focus away from other areas of healthcar...

Introduction: The COVID-19 pandemic has posed major challenges to all aspects of healthcare. Malta's population density, large proportion of elderly and high prevalence of diabetes and obesity put the country at risk of uncontrolled viral transmission and high mortality. Despite this, Malta achieved low mortality rates compared to figures overseas. The aim of this paper is to identify key factors that contributed to these favorable outcomes.

Methods: This is a retrospective, observational, nationwide study which evaluates outcomes of patients during the first wave of the pandemic in Malta, from the 7th of March to the 24th of April 2020. Data was collected on demographics and mode of transmission. Hospitalization rates to Malta's main general hospital, Mater Dei Hospital, length of in-hospital stay, intensive care unit admissions and 30-day mortality were also analyzed.

Results: There were 447 confirmed cases in total; 19.5% imported, 74.2% related to community transmission and 6.3% nosocomially transmitted. Ninety-three patients (20.8%) were hospitalized, of which 4 were children. Patients with moderate-severe disease received hydroxychloroquine and azithromycin, in line with evidence available at the time. A total of 4 deaths were recorded, resulting in an all-cause mortality of 0.89%. Importantly, all admitted patients with moderate-severe disease survived to 30-day follow up.

Conclusion: Effective public health interventions, widespread testing, remote surveillance of patients in the community and a low threshold for admission are likely to have contributed to these favorable outcomes. Hospital infection control measures were key in preventing significant nosocomial spread. These concepts can potentially be applied to stem future outbreaks of viral diseases. Patients with moderate-severe disease had excellent outcomes with no deaths reported at 30-day follow up.

This dataset is a per-state amalgamation of demographic, public health and other relevant predictors for COVID-19.

Deaths, Infections and Tests by State

The COVID Tracking Project: https://covidtracking.com/data/api

Used positive, death and totalTestResults from the API for, respectively, Infected, Deaths and Tested in this dataset. Please read the documentation of the API for more context on those columns

Predictor Data and Sources

Population (2020)

Density is people per meter squared https://worldpopulationreview.com/states/

ICU Beds and Age 60+

https://khn.org/news/as-coronavirus-spreads-widely-millions-of-older-americans-live-in-counties-with-no-icu-beds/

GDP

https://worldpopulationreview.com/states/gdp-by-state/

Income per capita (2018)

https://worldpopulationreview.com/states/per-capita-income-by-state/

Gini

https://en.wikipedia.org/wiki/List_of_U.S._states_by_Gini_coefficient

Unemployment (2020)

Rates from Feb 2020 and are percentage of labor force
https://www.bls.gov/web/laus/laumstrk.htm

Sex (2017)

Ratio is Male / Female
https://www.kff.org/other/state-indicator/distribution-by-gender/

Smoking Percentage (2020)

https://worldpopulationreview.com/states/smoking-rates-by-state/

Influenza and Pneumonia Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/flu_pneumonia_mortality/flu_pneumonia.htm

Chronic Lower Respiratory Disease Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/lung_disease_mortality/lung_disease.htm

Active Physicians (2019)

https://www.kff.org/other/state-indicator/total-active-physicians/

Hospitals (2018)

https://www.kff.org/other/state-indicator/total-hospitals

Health spending per capita

Includes spending for all health care services and products by state of residence. Hospital spending is included and reflects the total net revenue. Costs such as insurance, administration, research, and construction expenses are not included.
https://www.kff.org/other/state-indicator/avg-annual-growth-per-capita/

Pollution (2019)

Pollution: Average exposure of the general public to particulate matter of 2.5 microns or less (PM2.5) measured in micrograms per cubic meter (3-year estimate)
https://www.americashealthrankings.org/explore/annual/measure/air/state/ALL

Medium and Large Airports

For each state, number of medium and large airports https://en.wikipedia.org/wiki/List_of_the_busiest_airports_in_the_United_States

Temperature (2019)

Note that FL was incorrect in the table, but is corrected in the Hottest States paragraph
https://worldpopulationreview.com/states/average-temperatures-by-state/
District of Columbia temperature computed as the average of Maryland and Virginia

Urbanization (2010)

Urbanization as a percentage of the population https://www.icip.iastate.edu/tables/population/urban-pct-states

Age Groups (2018)

https://www.kff.org/other/state-indicator/distribution-by-age/

School Closure Dates

Schools that haven't closed are marked NaN https://www.edweek.org/ew/section/multimedia/map-coronavirus-and-school-closures.html

Note that some datasets above did not contain data for District of Columbia, this missing data was found via Google searches manually entered.

An in depth study on patients admitted to hospital and later deceased with the coronavirus (COVID-19) infection revealed that the majority of cases showed one or more comorbidities. About 67.8 percent of reported deceased COVID-19 patients suffered from three or more pre-existing health conditions, and 17.9 percent from two conditions. Only in 2.9 percent of COVID-19 deaths no prior health conditions were recorded. More statistics and facts about the virus in Italy are available here. For a global overview visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

Nursing homes with residents positive for COVID-19 from 4/22/2020 to 6/19/2020.

Starting in July 2020, this dataset will no longer be updated and will be replaced by the CMS COVID-19 Nursing Home Dataset, available at the following link: https://data.ct.gov/Health-and-Human-Services/CMS-COVID-19-Nursing-Home-Dataset/w8wc-65i5.

Methods: 1) Laboratory-confirmed case counts are based upon data reported via the FLIS web portal. Nursing homes were asked to provide cumulative totals of residents with laboratory confirmed covid. This includes residents currently in-house, in the hospital, or who are deceased. Residents were excluded if they tested positive prior to initial admission to the nursing home. 2) The cumulative number of deaths among nursing home residents is based upon data reported by the Office of the Chief Medical Examiner. For public health surveillance, COVID-19-associated deaths include persons who tested positive for COVID-19 around the time of death (laboratory-confirmed) and persons whose death certificate lists COVID-19 disease as a cause of death or a significant condition contributing to death (probable).

Limitations: 1) As of the week of 5/10/20, Point Prevalence Survey testing is being offered to all asymptomatic nursing home residents to inform infection prevention efforts. Point prevalence surveys will be conducted over a period of several weeks. Some nursing homes had adequate testing resources available to conduct surveys prior to this date. Differences in survey timing will impact the number of positive results that a nursing home reports. 2) Cumulative totals of residents testing positive are being collected rather than individual resident data. Thus we cannot verify the counts, de-duplicate, and/or verify whether there is a record of a positive lab test. This may result in either under- or over-counting. 3) The number of COVID-19 positive residents and the number of confirmed deaths among residents are tabulated from different data sources. Due to the timing of availability of test results for deceased residents, it is not appropriate to calculate the percent of cases who died due to COVID-19 at any particular facility based upon this data. 4) The count of deaths reported for 4/14 are not included in this dataset, as they were not broken out by laboratory-confirmed or probable. They can be viewed in the DPH Report here: https://portal.ct.gov/-/media/Coronavirus/CTDPHCOVID19summary4162020.pdf?la=en

The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

This dataset represents preliminary weekly estimates of cumulative U.S. COVID-19-associated hospitalizations for the 2024-2025 period. The weekly cumulatve COVID-19 –associated hospitalization estimates are preliminary, and use reported weekly hospitalizations among laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data are updated week-by-week as new COVID-19 hospitalizations are reported to CDC from the COVID-NET system and include both new admissions that occurred during the reporting week, as well as those admitted in previous weeks that may not have been included in earlier reporting. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated hospitalizations that have occurred since October 1, 2024. For details, please refer to the publication [7].

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

As of December, 2020, the coronavirus pandemic in the Netherlands resulted in over 527.5 thousand cases, 17.6 thousand hospital admissions, and 9.4 thousand deaths. To this day, most confirmed COVID-19 cases in the Netherlands were women. However, the distributions of hospital admissions and deaths due to the coronavirus were higher for men.

Gender aside, COVID-19 figures in the Netherlands differed in terms of age. According to Dutch numbers, the coronavirus infected mostly younger age groups. However, hospital admissions were higher in older people, while the coronavirus was especially deadly for people aged over 80.

OMOP dataset: Hospital COVID patients: severity, acuity, therapies, outcomes Dataset number 2.0

Coronavirus disease 2019 (COVID-19) was identified in January 2020. Currently, there have been more than 6 million cases & more than 1.5 million deaths worldwide. Some individuals experience severe manifestations of infection, including viral pneumonia, adult respiratory distress syndrome (ARDS) & death. There is a pressing need for tools to stratify patients, to identify those at greatest risk. Acuity scores are composite scores which help identify patients who are more unwell to support & prioritise clinical care. There are no validated acuity scores for COVID-19 & it is unclear whether standard tools are accurate enough to provide this support. This secondary care COVID OMOP dataset contains granular demographic, morbidity, serial acuity and outcome data to inform risk prediction tools in COVID-19.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. There is a higher than average percentage of minority ethnic groups. WM has a large number of elderly residents but is the youngest population in the UK. Each day >100,000 people are treated in hospital, see their GP or are cared for by the NHS. The West Midlands was one of the hardest hit regions for COVID admissions in both wave 1 & 2.

EHR. University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & 100 ITU beds. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”. UHB has cared for >5000 COVID admissions to date. This is a subset of data in OMOP format.

Scope: All COVID swab confirmed hospitalised patients to UHB from January – August 2020. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to care process (timings, staff grades, specialty review, wards), presenting complaint, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, microbiology, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes.

Available supplementary data: Health data preceding & following admission event. Matched “non-COVID” controls; ambulance, 111, 999 data, synthetic data. Further OMOP data available as an additional service.

Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.

Characteristics of hospital staff who developed immunoglobulin M antibody and subsequent PCR status.